Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01572753
Recruitment Status : Completed
First Posted : April 6, 2012
Last Update Posted : February 27, 2017
Information provided by (Responsible Party):
Novo Nordisk A/S

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : September 8, 2012
  Actual Study Completion Date : September 8, 2012